This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano
by Zacks Equity Research
PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.
3 Profitable Stocks Worth Investing in Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.
Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
3 Reasons Growth Investors Will Love Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.
Centene (CNC) Divests Apixio to Boost Its Core Business
by Zacks Equity Research
Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
Here is Why Growth Investors Should Buy Amphastar (AMPH) Now
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks.com featured highlights include Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings
by Zacks Equity Research
Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings are part of the Zacks Screen of the Week article.
4 Solid Profitable Stocks to Invest in Using Net Income Ratio
by Tirthankar Chakraborty
Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio.
Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?
by Zacks Equity Research
Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.
Factors That Make Ensign Group (ENSG) a Lucrative Bet Now
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
by Zacks Equity Research
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid Choice
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Amphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amphastar (AMPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 37.78% and 7.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Zacks.com featured highlights Amphastar, Alpha Metallurgical and Riley Exploration
by Zacks Equity Research
Amphastar, Alpha Metallurgical and Riley Exploration have been highlighted in this Screen of The Week article.